Old Drugs. New Prices. The Pharma Playbook Is Getting Sharper.
There’s a quiet shift happening across healthcare: medicines that were once “good enough” at older price points are being reintroduced—often with new labels, new indications, and new narrat…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s “third wheel” rule is supposed to be a footnote in the global drug supply chain. But the real story is what happens when patent filings stop being paperwork—and start acting like an early-warning system.
In a world where APIs (active pharmaceu…

Europe’s divisional patent game: how “final decisions” get delayed—and why it matters for generics
Big Pharma doesn’t always need to win in court. Sometimes, it just needs to keep the clock from running.
That’s the uncomfortable reality behind Europe’s…

Pharma patent litigation used to be a $50M problem.
Now, for some companies, it’s closer to $5M.
That’s not a pricing glitch—it’s a strategic shift. The kind that happens when legal teams stop treating patent disputes as inevitabilities and start treat…

PBMs and rebates aren’t “background noise” in pharma—they’re the operating system.
If you’re a pharma executive, payer strategy isn’t just a slide deck topic anymore. It’s the difference between a launch that scales and a launch that stalls quietly i…

Mark Cuban’s cost-plus pricing isn’t just another pricing headline—it’s a direct challenge to the patent playbook that has quietly governed U.S. drug economics for decades.
Here’s the agitation: for years, the industry’s story has been consistent. Pate…

Should you file a provisional patent for your drug invention? The honest answer.
In biotech, the clock starts ticking the moment you have something real—not when you feel ready.
That’s why the question “Should I file a provisional patent?” keeps coming…

Don’t Wait for the Patent Cliff—Build Pharmaceutical Supply-Chain Resilience Years Before Expiration
The “patent cliff” isn’t a cliff you can see from the boardroom window. It’s a slow-motion event—quietly scheduled, legally defined, and operationally …

The 180-Day FDA Exclusivity Race Isn’t a Sprint—It’s a Strategy War. Here’s the Playbook.
If you’re in generic or biosimilar development, you already know the headline: the first applicant to win the “180-day exclusivity” clock can capture outsized mar…